Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 04:58 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
QAX576 in Patients With Pulmonary Fibrosis Secondary to Systemic Sclerosis
NCT00581997 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2020-12-19 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Concerns about risk of bronchoscopy procedure in the selected patient population and frequency of SAEs observed to date.” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IL13 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2021-12-08Phase 3 first posted: Almirall, S.A., Lebrikizumab + Lebrikizumab-matching Placebo (NCT05149313)
- 2021-10-29Results posted on the registry: LEO Pharma, Tralokinumab + Placebos (NCT03526861)
- 2021-10-26Results posted on the registry: LEO Pharma, Tralokinumab (NCT03761537)
- 2021-08-05Phase 3 first posted: Celgene, CC-93538 (NCT04991935)
- 2021-05-04Results posted on the registry: Eli Lilly and Company, Lebrikizumab + Placebo (NCT03443024)
- 2021-03-05Results posted on the registry: LEO Pharma, Tralokinumab + Placebo (NCT03562377)
- 2021-02-18Phase 3 first posted: Eli Lilly and Company, Lebrikizumab + Placebo (NCT04760314)
- 2021-02-15Phase 3 first posted: Celgene, CC-93538 (NCT04753697)
- 2021-01-14Results posted on the registry: LEO Pharma, Tralokinumab + Placebo (NCT03363854)
- 2020-12-19Also stopped (terminated): Novartis Pharmaceuticals, QAX576 + QAX576 placebo (NCT00987545)
- 2020-12-19Also stopped (terminated): Novartis Pharmaceuticals, QAX576 + Placebo (NCT01266135)
- 2020-11-20Results posted on the registry: LEO Pharma, Tralokinumab + Placebo (NCT03131648)
- 2020-11-12Phase 3 first posted: Eli Lilly and Company, Lebrikizumab + Placebo (NCT04626297)
- 2020-10-14Phase 3 first posted: LEO Pharma, Tralokinumab + Placebo (NCT04587453)
- 2020-08-24Results posted on the registry: LEO Pharma, Tralokinumab + Placebo (NCT03160885)
- 2020-05-18Phase 3 first posted: Eli Lilly and Company, Lebrikizumab (NCT04392154)
- 2020-01-31Phase 3 first posted: Eli Lilly and Company, Lebrikizumab (NCT04250350)
- 2020-01-31Phase 3 first posted: Eli Lilly and Company, Lebrikizumab (NCT04250337)
- 2020-01-07Results posted on the registry: Emma Guttman, Tralokinumab + Placebo (NCT02684097)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision